How Gilead Is Building Durable Oncology and Immunology Franchises

Episode Summary

Executive Summary: Gilead is trying to diversify beyond HIV while preserving its virology leadership by pairing internal R&D with targeted acquisitions, tighter scientific filters, and broader use of AI. Dietmar Berger says the company now prioritizes mechanistic validation, transformative clinical impact, and platform-building assets across oncology and immunology, with synergy potential across modalities and therapeutic areas.

Main Topics: Portfolio diversification beyond HIV (Priority: 5/5): Berger describes Gilead’s challenge as moving from a virology-heavy revenue base toward a more balanced company spanning virology, oncology, and immunology, without abandoning HIV leadership. Science-first business development and acquisitions (Priority: 5/5): The company uses acquisitions selectively to add both near-term therapeutic candidates and durable platforms, emphasizing differentiated science, validated mechanisms, and broader applicability. Learning from past bets and portfolio balance (Priority: 4/5): Berger acknowledges some oncology programs underperformed, and says this has reinforced the need for a portfolio mix of higher-risk early programs and more de-risked assets with clearer validation. Therapeutic area overlap and platform synergies (Priority: 4/5): He argues there is scientific continuity across virology, oncology, and immunology, especially in immune modulation, CAR T, and ADCs, allowing capabilities to transfer across disease areas. Mechanistic rigor as an investment filter (Priority: 5/5): Before committing serious resources, Gilead wants clear target biology, biomarkers, preclinical readouts, and confidence that a modality can translate into clinical benefit. AI and digital tools across R&D (Priority: 4/5): Gilead is using AI for protein structure, trial recruitment, protocol drafting, safety signal detection, and modeling/simulation, and sees larger future gains in strategic decision-making and indication selection. R&D organization and integration of external innovation (Priority: 3/5): New acquisitions are not just products but capability builders that reshape internal R&D structures, such as creating an ADC innovation center and integrating external science into the core organization.

Key Arguments: Gilead wants to remain a leader in virology while building equally strong positions in oncology and immunology, creating a more diversified revenue mix over time. Acquisitions are pursued not only for a lead asset but also for platform value and scientific capabilities that can be extended into future programs. The company’s investment bar has tightened: it now looks more critically at mechanism, unmet need, competitive landscape, probability of success, cost, and timelines. Clinical impact, not market hype, is the main criterion; Gilead will not pursue areas where it cannot make a meaningful difference or where the field is already saturated. Lessons from HIV and hepatitis C include deep biology/chemistry expertise, rapid iteration, and openness to external innovation when it is scientifically superior. There is meaningful overlap among virology, oncology, and immunology because all involve manipulating immune responses and disease-causing cells, enabling cross-application of modalities like CAR T and ADCs. AI is already improving operational efficiency and may increasingly shape strategic choices by integrating literature, omics, real-world evidence, and competitive intelligence. R&D is becoming more integrated across internal and external innovation sources, with acquisitions feeding back into strategy, structure, and technical capabilities.

Data Points: HIV revenue share: roughly two-thirds of total revenue - Gilead’s HIV and broader virology business still dominates company revenue. Oncology scale: mid-single-digit billion-dollar franchise - Oncology has grown into a meaningful but still smaller business line. Inflammation/immunology pipeline: 3 products in phase 2 and more than 10 medicines in development - Berger characterizes immunology as an earlier-stage portfolio. Acquisitions cited: Kite (2017), Immunomedics (2020), Celix (2025), Tubulis, Ouro Medicines - Examples of Gilead’s external innovation strategy and platform-building M&A. Trial recruitment improvement: factor of two or more - Berger says AI-enabled patient identification has materially improved clinical trial recruitment. AI utilization scope: across the R&D continuum - Gilead is already using AI in structure prediction, recruitment, protocols, safety analytics, and modeling. Model-informed drug development: used in early development and, in specific instances, entire new drug submissions - He cites regulatory acceptance of modeling/simulation and digital twins. Internal/external innovation ratio: 99% of innovation is external - Berger uses this to explain why Gilead remains highly open to external science.

Pivotal Quotes: "We want to lead in those three areas and we want to get to a more diversified picture." — Dietmar Berger: Describing Gilead’s long-term revenue and portfolio vision across virology, oncology, and immunology. "We're really interested in transformative medicines, transformative approaches that can move patient care forward." — Dietmar Berger: Explaining the company’s business development filter and why clinical impact matters more than hype. "We have to understand the underlying biology. What actually is the mechanism that leads to disease?" — Dietmar Berger: Discussing the level of mechanistic validation needed before major internal investment or acquisition.

Implications: Gilead is positioning itself as a science-driven platform company, not just an HIV leader. Expect more selective deal-making, more cross-therapeutic platform reuse, heavier AI adoption, and a higher bar for programs that lack clear mechanistic or clinical differentiation.